Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.
• Patient is ≥18 years of age
• Written Informed Consent provided by patient
• Diagnosis of any kind of carcinoma
• Malignant fluid (e.g. pleural effusion or ascites) drainage OR tumor tissue resection OR tumor tissue needle biopsy is clinically indicated as part of SOC
• Proceeding onto therapy for treatment
• Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088)